Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurie, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurie, J. M.
(Chest. 2004;125:141S-144S.)
© 2004 American College of Chest Physicians

Role of Protein Kinase B-Dependent Signaling in Lung Tumorigenesis*

Jonathan M. Kurie, MD

* From the Department of Thoracic/Head and Neck Medical Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, TX.

Correspondence to: Jonathan M. Kurie, MD, Box 432, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: jkurie{at}mdanderson.org

Recent studies have defined the survival pathways activated by receptor tyrosine kinases that are critical in the transformation of human bronchial epithelial cells and in maintaining the survival of non-small cell lung cancer (NSCLC) cells. Protein kinase B (AKT) is one element of receptor tyrosine kinase signaling that is activated in bronchial premalignancy and NSCLC. Recent studies have shown that AKT cooperates with the stress kinase mitogen-activated protein kinase kinase 4 to maintain the survival of NSCLCs. These studies illustrate the importance of understanding the interactions between survival pathways and developing inhibitors to specific kinases that can be used alone or in combination in clinical trials for lung cancer prevention and treatment.

Key Words: non-small cell lung cancer • protein kinase B • mitogen-activated kinase kinase-4






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Chest Physicians.